Stay updated with breaking news from Ken Blount. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Discover the contributions of Ken Blount to federal healthcare IT markets. Learn how he mastered various facets of the information networks of the DoD.
RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.
Patients with C. difficile who received clonal bacteria populations via biotherapeutic injection were able to repopulate their microbiota with commensal bacteria.
/PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG), an independent 501(c)(6) coalition of companies leading the research and development of...
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022.